A study in Breast Cancer Research links metabolic response on [18F]FDG PET/CT with longer progression-free survival in advanced breast cancer patients receiving CDK4/6 inhibitors. The work focuses on how imaging-derived metabolic changes align with clinical outcomes. While PET/CT findings are not the same as a regulatory endpoint, the result supports using metabolic response measures as a potentially earlier signal of treatment activity for CDK4/6 regimens. For clinical teams, such imaging markers can inform adaptive decisions in trials and may support refined assessment strategies in real-world practice, particularly when disease monitoring schedules are constrained. The record provided does not include effect sizes or hazard ratios, limiting the ability to compare with other response metrics.